Navigation Links
Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology

the disease, which has no known cause.

About Critical Therapeutics

Critical Therapeutics, headquartered Lexington, MA, is developing and commercializing innovative products for respiratory, inflammatory and critical care diseases. The Company owns worldwide rights to ZYFLO(R) (zileuton tablets), which is marketed in the United States for the prevention and chronic treatment of asthma in patients 12 years of age and older. Critical Therapeutics is working to expand its zileuton franchise by developing a twice daily, controlled-release formulation for the prevention and chronic treatment of asthma and an injectable formulation for acute asthma attacks that lead patients to the emergency room and other urgent care settings. The Company also is collaborating with MedImmune, Inc. to design antibody therapies that treat acute and chronic diseases triggered by the inflammatory cytokine HMGB1. Research pipeline programs include lifecycle management to extend the zileuton franchise and an alpha-7 project for the treatment of inflammation. For more information, please visit www.crtx.com.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Critical Therapeutics, Inc., including, without limitation, regarding the potential role of HMGB1 in diagnosing and treating disease; the progress, timing and plans for the HMGB1 program; the timing and success of regulatory filings, regulatory approvals and product launches; the efficacy of our drug candidates; prospects, plans and objectives of management; and all other statements that are not purely historical in nature, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "project," "should," "will," "would" and similar expressions are intended to identify forward-l
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. NIEHS Researchers Identify Enzyme Critical in DNA Replication
2. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
3. Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma
4. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development
5. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
6. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
7. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
10. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
11. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients

Post Your Comments:
(Date:11/25/2009)... , CHAPEL HILL, N.C., Nov. 25 ...rabhavathi Fernandes, president and chief executiv...Annual Health Care Conference at 8:50 a.m. EST, De...w York City. Dr. Fernandes will provide an overvi...l programs for the treatment of drug-resistant pat...
(Date:11/25/2009)..., FRAMINGHAM, Mass. and SYDNEY, Nov. 25 /PRNews...Nasdaq: HTWR ; ASX: HIN), a leading innovator and...ry support technologies revolutionizing the treatm...t it is scheduled to make an investor presentation...erence at 8:00 am EST on Wednesday, December 2, 20...
(Date:11/24/2009)..., IRVINE, Calif., Nov. 24 /PRNewswire-FirstCall/ ...minimally invasive treatments for aortic disorders...ay, or discontinue all proceedings in, the patent ... 2009 by Cook, Inc. The motion was filed in the U...na. ,, Endologix has requested that the stay re...
Breaking Medicine Technology:HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City 2Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2Hospital Workers May Trigger Dangerous Outbreaks 59765 1Hospital Workers May Trigger Dangerous Outbreaks 59765 2Hospital Workers May Trigger Dangerous Outbreaks 59765 3Pediatricians put proven treatment strategies to work against childhood asthma 59760 1Pediatricians put proven treatment strategies to work against childhood asthma 59760 2Global warming may spur increased growth in Pacific Northwest forests 10416 1Global warming may spur increased growth in Pacific Northwest forests 10416 2Global warming may spur increased growth in Pacific Northwest forests 10416 3
...AGEN donates one million tests to expand access to... , VENLO, Netherlands, April 1 Results from an e...published today in The New England Journal of Med...tings a single round of HPV testing significantly ...nd deaths, compared with Pap (cytology) testing or...
...NVER, April 1 Responding to President Obama,s cal...eutical Research and Manufacturers of America (PhR...he research pipeline for cancer. The report shows ...nology companies are testing a record 861 new canc... the report are being tested in human clinical tri...
Other Medicine Technology:Landmark Study in The New England Journal of Medicine Shows HPV Testing Significantly Reduces Deaths from Cervical Cancer, Compared to other Methods Including Pap 2Landmark Study in The New England Journal of Medicine Shows HPV Testing Significantly Reduces Deaths from Cervical Cancer, Compared to other Methods Including Pap 3Landmark Study in The New England Journal of Medicine Shows HPV Testing Significantly Reduces Deaths from Cervical Cancer, Compared to other Methods Including Pap 4Landmark Study in The New England Journal of Medicine Shows HPV Testing Significantly Reduces Deaths from Cervical Cancer, Compared to other Methods Including Pap 5New Report Shows Record Number of Medicines in Development to Treat Leading Causes of Cancer 2New Report Shows Record Number of Medicines in Development to Treat Leading Causes of Cancer 3New Report Shows Record Number of Medicines in Development to Treat Leading Causes of Cancer 4
(Date:11/27/2009)...Newswire-FirstCall/ -- Shamir Optical Industry Ltd...r of innovative products and technology to the oph...d of directors had declared a dividend distributio...imately NIS 37.62 million based on the November 25...imately US$ 0.609 (approximately NIS 2.3 based on ...
(Date:11/27/2009)... announced today that Spectrum Health (Grand Rapid... orthopedic templating solution and its TraumaCad ... (PRWEB) November 27, 2009 -- Voyant Health&trad...ids, Michigan) has licensed its TraumaCad Enterpri...d Extend workflow solution, to allow its orthopedi...
(Date:11/26/2009)...wire/ -- The diabetes population in the United Sta...annual medical spending on the disease is projecte... according to a study published in the December is...abetes ® Program (NCDP), a program of Novo No...e University of Chicago. ,, According to the fo...
(Date:11/26/2009)... the North Pole, Textsanta.net lets parents sign u... North Pole, AK (PRWEB) -- In ...the North Pole Santa Claus has added SMS text mess...ormed of his Christmas progress at the North Pole....ve identified a large and growing percentage of Am...
(Date:11/25/2009)...USNewswire/ -- When most people hear the acronym T...or can also give patients the help they need. TMJ ... where your jaw (mandible) contacts/connects with ... symptoms associated with TMJ dysfunction are pain...t many other symptoms can be caused from TMJ dysfu...
Breaking Medicine News(10 mins):Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2
...pt. 21 Cephalon, Inc. (Nasdaq:,CEPH) today announ...NDA) to,the U.S. Food and Drug Administration (FDA...HCl) for the treatment of patients with chronic,ly...ted States, according to the National Cancer Insti...
...he right grains for breakfast, such as whole-grain... is facilitated after breakfast, lunch, and dinner...rain products have this effect all day. This is du...esented in a dissertation from the Faculty of Engi...
... Sept. 14, 2007 -- A new study by researchers at t... some TV may be good for you. , Researchers foun...ama ER that dealt with teen obesity, hypertension .... 14 Journal of Health Communication and now avail...
...produce treatments to kill off cancer cells, exper...information about a process called unplanned cell ...t heart disease, cancer, stroke and other life-thr...death caused by outside factors, such as traumatic...
...., Sept. 21 Schering-Plough,Corporation (NYSE: S...gs,results for the 2007 third quarter on Monday, O...ng-Plough will conduct a conference,call to review...o listen live to the call, dial 1-877-565-9664 or ...
...Sept. 21 A sellout crowd will honor,Texas House S...t the 5th,Annual Speaker,s Golf Tournament, an eve...nt of money raised by last year,s tournament, with... event, proceeds from the tournament have snowball...
Other Medicine News:Health News:Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 2Health News:Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 3Health News:Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 4Health News:Right breakfast bread keeps blood sugar in check all day 2Health News:ER episode impacts viewers' health knowledge and behavior 2Health News:Clues to Cell Death Could Fight Disease 2Health News:2007 Speaker's Golf Tournament Sets 5-Year Fundraising Record 2
Kratz-Barraquer Eye Speculum
Lehner Temporal Speculum
Wiener Eye Speculum
McKinney Eye Speculum
Medicine Products: